Insulet (PODD) Other Non-Current Assets (2010 - 2026)
Insulet (PODD) posted Other Non-Current Assets of $280.6 million for Q1 2026, down 2.64% on a QoQ basis from $288.2 million in Q4 2025, and down 12.01% year-over-year from $318.9 million in Q1 2025.
Insulet (PODD) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Insulet's Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $280.6 million for Q1 2026.
- Quarterly Other Non-Current Assets fell 12.01% year-over-year to $280.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $280.6 million (down 12.01% YoY) and the FY2025 annual result came in at $288.2 million, up 58.79% from the prior year.
- Other Non-Current Assets was $280.6 million for Q1 2026 at Insulet, down from $288.2 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $318.9 million in Q1 2025 and bottomed at $141.0 million in Q1 2022.
- A 5-year average of $211.1 million and a median of $188.3 million in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 97.93% — and 2024, when it retreated 22.68%.
- Insulet's Other Non-Current Assets stood at $210.0 million in 2022, then declined by 10.38% to $188.2 million in 2023, then decreased by 3.56% to $181.5 million in 2024, then jumped by 58.79% to $288.2 million in 2025, then fell by 2.64% to $280.6 million in 2026.
- Business Quant data shows PODD's Other Non-Current Assets at $280.6 million in Q1 2026, $288.2 million in Q4 2025, and $188.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 3.17 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 4.15 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 2.05 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 738.90 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 285.90 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 2.25 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | 164.00 Mn |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 828.89 Mn |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | 280.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 280.60 Mn |
| Dec 31, 2025 | 288.20 Mn |
| Sep 30, 2025 | 188.30 Mn |
| Jun 30, 2025 | 315.10 Mn |
| Mar 31, 2025 | 318.90 Mn |
| Dec 31, 2024 | 181.50 Mn |
| Sep 30, 2024 | 165.90 Mn |
| Jun 30, 2024 | 163.60 Mn |
| Mar 31, 2024 | 187.70 Mn |
| Dec 31, 2023 | 188.20 Mn |
| Sep 30, 2023 | 196.20 Mn |
| Jun 30, 2023 | 211.60 Mn |
| Mar 31, 2023 | 210.60 Mn |
| Dec 31, 2022 | 210.00 Mn |
| Sep 30, 2022 | 178.70 Mn |
| Jun 30, 2022 | 161.90 Mn |
| Mar 31, 2022 | 141.00 Mn |
| Dec 31, 2021 | 106.10 Mn |
| Sep 30, 2021 | 99.60 Mn |
| Jun 30, 2021 | 92.00 Mn |